arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

LivaNova PLC

LIVN
$77.21 ▼ -1.24 (-1.58%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
52 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
43
Health
Weak
Bearish
auto_awesome

Analytical Summary

LivaNova PLC faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.2B
Dividend Yield —
Revenue Growth 10.8% ↘
Op. Margin 12.7% ↗
ROIC 2.4% ↗
FCF / Share $0.64 ↗
Trailing P/E 39.0x
Price / Book 3.2x
FCF Yield 0.8%
Debt / Equity 0.22
info Valuation on last close. End-of-day price, Sep 23, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$390.59M
↑ +10.8% —
Net Income Profit after all expenses
$108.57M
↑ +299.7% —
Operating Margin Operating profit as % of sales
12.7%
↑ +10.7% 66th
FCF / Share Free cash flow per share
$0.64
↑ +3664.3% —
Long-Term Debt Long-term obligations
$290.08M
↑ +1.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
48
Returns ↓
28
Financial Health ↑
70
Cash Quality ↓
12

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 52 quarters